Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases.
High growth potential with mediocre balance sheet.
Share Price & News
How has Insmed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IM8N's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: IM8N underperformed the German Biotechs industry which returned -13.5% over the past year.
Return vs Market: IM8N underperformed the German Market which returned -20.9% over the past year.
Price Volatility Vs. Market
How volatile is Insmed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Insmed undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IM8N (€16.1) is trading below our estimate of fair value (€56.64)
Significantly Below Fair Value: IM8N is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IM8N is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: IM8N is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IM8N's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IM8N is overvalued based on its PB Ratio (6.1x) compared to the DE Biotechs industry average (3.3x).
How is Insmed forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IM8N is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: IM8N is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IM8N's is expected to become profitable in the next 3 years.
Revenue vs Market: IM8N's revenue (36.4% per year) is forecast to grow faster than the German market (4% per year).
High Growth Revenue: IM8N's revenue (36.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IM8N is forecast to be unprofitable in 3 years.
How has Insmed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IM8N is currently unprofitable.
Growing Profit Margin: IM8N is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IM8N is unprofitable, and losses have increased over the past 5 years at a rate of -26% per year.
Accelerating Growth: Unable to compare IM8N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IM8N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: IM8N has a negative Return on Equity (-97.2%), as it is currently unprofitable.
How is Insmed's financial position?
Financial Position Analysis
Short Term Liabilities: IM8N's short term assets ($555.2M) exceed its short term liabilities ($85.2M).
Long Term Liabilities: IM8N's short term assets ($555.2M) exceed its long term liabilities ($395.4M).
Debt to Equity History and Analysis
Debt Level: IM8N's debt to equity ratio (128.4%) is considered high.
Reducing Debt: IM8N's debt to equity ratio has increased from 8.7% to 128.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IM8N has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IM8N has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Insmed's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IM8N's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IM8N's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IM8N's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IM8N's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IM8N's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Will Lewis (50yo)
Mr. William H. Lewis, J.D., M.B.A., also known as Will, has been Chief Executive Officer and President at Insmed Incorporated since September 11, 2012 and has been its Chairman of Board since November 6, 2 ...
CEO Compensation Analysis
Compensation vs Market: Will's total compensation ($USD5.94M) is above average for companies of similar size in the German market ($USD1.93M).
Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.
|Chief Operating Officer||0.42yr||US$2.67m||0.014% $200.7k|
|Chief Legal Officer & Corporate Secretary||6.75yrs||US$2.03m||0.042% $615.1k|
|Chief Financial Officer||0.25yr||no data||no data|
|Senior VP & Chief Accounting Officer||1.08yrs||no data||0.0039% $57.0k|
|Chief Technology Officer||9.33yrs||no data||no data|
|Chief Compliance Officer||2.25yrs||no data||0.0031% $45.3k|
|Senior Director of Corporate Communications||no data||no data||no data|
|Chief People Strategy Officer||7.25yrs||US$1.56m||0.0056% $82.9k|
Experienced Management: IM8N's management team is considered experienced (2.3 years average tenure).
|Independent Director||20.42yrs||US$225.00k||0.31% $4.6m|
|Independent Director||6.5yrs||US$225.00k||0.039% $582.4k|
|Independent Director||18.92yrs||US$217.00k||0.28% $4.1m|
|Independent Director||7.67yrs||US$230.00k||0.029% $427.3k|
|Lead Independent Director||1.42yrs||US$215.80k||0.054% $796.0k|
|Independent Director||0.42yr||no data||no data|
|Independent Director||1.42yrs||US$91.97k||0.0057% $84.4k|
|Independent Director||1.92yrs||US$190.17k||0.018% $264.6k|
|Director||no data||no data||no data|
Experienced Board: IM8N's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.
Insmed Incorporated's company bio, employee growth, exchange listings and data sources
- Name: Insmed Incorporated
- Ticker: IM8N
- Exchange: DB
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.597b
- Listing Market Cap: US$1.480b
- Shares outstanding: 89.86m
- Website: https://www.insmed.com
Number of Employees
- Insmed Incorporated
- 700 US Highway 202/206
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|INSM||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 2000|
|IM8N||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2000|
|IM8N||BST (Boerse-Stuttgart)||Yes||Common Stock||DE||EUR||Jun 2000|
|0JAV||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jun 2000|
|IM8N||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||Jun 2000|
|INSM *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jun 2000|
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/06 22:57|
|End of Day Share Price||2020/04/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.